Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.19
NAVB's Cash to Debt is ranked lower than
93% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. NAVB: 0.19 )
Ranked among companies with meaningful Cash to Debt only.
NAVB' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 1.66 Max: No Debt
Current: 0.19
Equity to Asset -2.99
NAVB's Equity to Asset is ranked lower than
98% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAVB: -2.99 )
Ranked among companies with meaningful Equity to Asset only.
NAVB' s Equity to Asset Range Over the Past 10 Years
Min: -3.6  Med: 0.40 Max: 0.94
Current: -2.99
-3.6
0.94
F-Score: 4
Z-Score: -33.95
M-Score: -3.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -183.14
NAVB's Operating margin (%) is ranked lower than
59% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. NAVB: -183.14 )
Ranked among companies with meaningful Operating margin (%) only.
NAVB' s Operating margin (%) Range Over the Past 10 Years
Min: -35429.11  Med: -250.97 Max: -19.17
Current: -183.14
-35429.11
-19.17
Net-margin (%) -286.18
NAVB's Net-margin (%) is ranked lower than
65% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. NAVB: -286.18 )
Ranked among companies with meaningful Net-margin (%) only.
NAVB' s Net-margin (%) Range Over the Past 10 Years
Min: -36907.59  Med: -249.70 Max: 938.63
Current: -286.18
-36907.59
938.63
ROA (%) -199.08
NAVB's ROA (%) is ranked lower than
93% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. NAVB: -199.08 )
Ranked among companies with meaningful ROA (%) only.
NAVB' s ROA (%) Range Over the Past 10 Years
Min: -502.64  Med: -101.25 Max: 26.69
Current: -199.08
-502.64
26.69
ROC (Joel Greenblatt) (%) -1053.18
NAVB's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. NAVB: -1053.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAVB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8007.05  Med: -859.69 Max: -117.97
Current: -1053.18
-8007.05
-117.97
Revenue Growth (3Y)(%) 58.70
NAVB's Revenue Growth (3Y)(%) is ranked higher than
93% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAVB: 58.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAVB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -5.30 Max: 89.8
Current: 58.7
-100
89.8
EBITDA Growth (3Y)(%) -8.00
NAVB's EBITDA Growth (3Y)(%) is ranked lower than
57% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. NAVB: -8.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAVB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -16.60 Max: 141
Current: -8
0
141
EPS Growth (3Y)(%) 7.90
NAVB's EPS Growth (3Y)(%) is ranked higher than
66% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NAVB: 7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAVB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.9  Med: 4.35 Max: 112
Current: 7.9
-43.9
112
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015
Q2 2015
Q3 2015
Q4 2015
» Details

Insider Trades

Latest Guru Trades with NAVB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 12.23
NAVB's P/S is ranked lower than
58% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. NAVB: 12.23 )
Ranked among companies with meaningful P/S only.
NAVB' s P/S Range Over the Past 10 Years
Min: 1.9  Med: 16.75 Max: 479
Current: 12.23
1.9
479
Current Ratio 2.40
NAVB's Current Ratio is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. NAVB: 2.40 )
Ranked among companies with meaningful Current Ratio only.
NAVB' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 2.86 Max: 17.92
Current: 2.4
0.62
17.92
Quick Ratio 2.26
NAVB's Quick Ratio is ranked lower than
67% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NAVB: 2.26 )
Ranked among companies with meaningful Quick Ratio only.
NAVB' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 2.31 Max: 17.8
Current: 2.26
0.48
17.8
Days Inventory 220.46
NAVB's Days Inventory is ranked lower than
74% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. NAVB: 220.46 )
Ranked among companies with meaningful Days Inventory only.
NAVB' s Days Inventory Range Over the Past 10 Years
Min: 98.26  Med: 135.77 Max: 1386.56
Current: 220.46
98.26
1386.56
Days Sales Outstanding 62.48
NAVB's Days Sales Outstanding is ranked higher than
52% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NAVB: 62.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAVB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.77  Med: 76.68 Max: 1211.54
Current: 62.48
9.77
1211.54
Days Payable 304.91
NAVB's Days Payable is ranked higher than
89% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. NAVB: 304.91 )
Ranked among companies with meaningful Days Payable only.
NAVB' s Days Payable Range Over the Past 10 Years
Min: 31.95  Med: 92.64 Max: 2654.74
Current: 304.91
31.95
2654.74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.78
NAVB's Price/Median PS Value is ranked higher than
60% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. NAVB: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
NAVB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.27 Max: 24.53
Current: 0.78
0.04
24.53
Price/Graham Number 0.71
NAVB's Price/Graham Number is ranked higher than
81% of the 431 Companies
in the Global Biotechnology industry.

( Industry Median: 2.37 vs. NAVB: 0.71 )
Ranked among companies with meaningful Price/Graham Number only.
NAVB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.62  Med: 1.50 Max: 12.62
Current: 0.71
0.62
12.62
Earnings Yield (Greenblatt) (%) -12.95
NAVB's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. NAVB: -12.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NAVB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -14.2  Med: 0.00 Max: 0
Current: -12.95
-14.2
0

More Statistics

Revenue(Mil) $11
EPS $ -0.21
Beta-0.04
Short Percentage of Float20.90%
52-Week Range $0.75 - 2.50
Shares Outstanding(Mil)155.70

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc was incorporated in Ohio in 1983 and reincorporated in Delaware in 1988. It is a biopharmaceutical company engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma. Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages. This flexible and versatile platform acts as an engine for the design of purpose-built molecules offering the potential to be utilized across a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography, intra-operative and/or optical-fluorescence detection in a variety of disease states. NAV4694 is a Fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. NAV5001 is an Iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with potential use as a diagnostic aid in dementia. NAV1800 is a radiolabeled monoclonal antibody being developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, with a focus on colorectal cancer. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

More From Other Websites
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure Feb 11 2016
Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek® Feb 11 2016
Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor Conference Feb 04 2016
Navidea Provides Update on Lymphoseek® and Immunodiagnostics Development Pipeline Feb 02 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 11 2016
Navidea Meets Guidance With 2015 Unaudited Lymphoseek® Sales of $10.2 Million Jan 11 2016
Navidea Appoints Anton Gueth Chairman of the Board Jan 11 2016
Navidea Meets Guidance With 2015 Unaudited Lymphoseek® Sales of $10.2 Million Jan 11 2016
Navidea Appoints Anton Gueth Chairman of the Board Jan 11 2016
Navidea Biopharmaceuticals Enrolls First Patient in Pediatric Trial of Lymphoseek® Jan 06 2016
Navidea Biopharmaceuticals Enrolls First Patient in Pediatric Trial of Lymphoseek® Jan 06 2016
Navidea Biopharmaceuticals to Present at Biotech Showcase 2016 Jan 04 2016
Navidea Biopharmaceuticals to Present at Biotech Showcase 2016 Jan 04 2016
Navidea Biopharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
Lymphoseek® Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients... Dec 10 2015
Lymphoseek® Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients... Dec 10 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Financials Dec 08 2015
Lymphoseek® Reduces Sentinel Lymph Node Biopsy Imaging Time, Facilitating Patient Throughput and... Dec 03 2015
Lymphoseek® Reduces Sentinel Lymph Node Biopsy Imaging Time, Facilitating Patient Throughput and... Dec 03 2015
Do Hedge Funds Love Navidea Biopharmaceuticals Inc (NAVB)? Nov 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK